Moreover, NSCLC patients with positive PD-L1 expression had a poorer prognosis than those with negative PD-L1 expression following radiotherapy.7,8 However, in the PACIFIC study, patients with PD-L1 expression levels lower than 25% obtain similar survival benefits to patients with higher PD-L1 levels, which demonstrated that PD-L1 alone was not a reliable predictor of radiotherapy efficacy. Here, CD274 is linked to non-small cell lung carcinoma.